Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007200113 | Prostate | Tumor | renal system development | 75/3246 | 302/18723 | 5.74e-04 | 4.13e-03 | 75 |
GO:007216013 | Prostate | Tumor | nephron tubule epithelial cell differentiation | 8/3246 | 14/18723 | 8.99e-04 | 5.96e-03 | 8 |
GO:003433213 | Prostate | Tumor | adherens junction organization | 17/3246 | 49/18723 | 2.61e-03 | 1.43e-02 | 17 |
GO:007200913 | Prostate | Tumor | nephron epithelium development | 31/3246 | 109/18723 | 2.70e-03 | 1.48e-02 | 31 |
GO:007208013 | Prostate | Tumor | nephron tubule development | 26/3246 | 91/18723 | 5.32e-03 | 2.54e-02 | 26 |
GO:007200613 | Prostate | Tumor | nephron development | 37/3246 | 142/18723 | 5.73e-03 | 2.67e-02 | 37 |
GO:006132612 | Prostate | Tumor | renal tubule development | 26/3246 | 94/18723 | 8.40e-03 | 3.66e-02 | 26 |
GO:00070093 | Prostate | Tumor | plasma membrane organization | 36/3246 | 142/18723 | 1.00e-02 | 4.20e-02 | 36 |
GO:003585012 | Prostate | Tumor | epithelial cell differentiation involved in kidney development | 15/3246 | 47/18723 | 1.07e-02 | 4.45e-02 | 15 |
GO:004521626 | Skin | AK | cell-cell junction organization | 51/1910 | 200/18723 | 4.51e-10 | 5.24e-08 | 51 |
GO:005067319 | Skin | AK | epithelial cell proliferation | 86/1910 | 437/18723 | 1.52e-09 | 1.43e-07 | 86 |
GO:000701528 | Skin | AK | actin filament organization | 85/1910 | 442/18723 | 5.94e-09 | 4.14e-07 | 85 |
GO:190290328 | Skin | AK | regulation of supramolecular fiber organization | 75/1910 | 383/18723 | 2.11e-08 | 1.20e-06 | 75 |
GO:003297028 | Skin | AK | regulation of actin filament-based process | 76/1910 | 397/18723 | 4.61e-08 | 2.37e-06 | 76 |
GO:005067818 | Skin | AK | regulation of epithelial cell proliferation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
GO:003295628 | Skin | AK | regulation of actin cytoskeleton organization | 66/1910 | 358/18723 | 1.40e-06 | 4.26e-05 | 66 |
GO:005101728 | Skin | AK | actin filament bundle assembly | 36/1910 | 157/18723 | 2.48e-06 | 6.76e-05 | 36 |
GO:006157228 | Skin | AK | actin filament bundle organization | 36/1910 | 161/18723 | 4.59e-06 | 1.10e-04 | 36 |
GO:011005328 | Skin | AK | regulation of actin filament organization | 53/1910 | 278/18723 | 5.48e-06 | 1.26e-04 | 53 |
GO:003223126 | Skin | AK | regulation of actin filament bundle assembly | 25/1910 | 105/18723 | 4.19e-05 | 6.70e-04 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTSS1 | SNV | Missense_Mutation | | c.923C>G | p.Ser308Cys | p.S308C | O43312 | protein_coding | tolerated(0.11) | probably_damaging(1) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MTSS1 | SNV | Missense_Mutation | | c.294C>A | p.Ser98Arg | p.S98R | O43312 | protein_coding | tolerated(0.06) | probably_damaging(0.988) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
MTSS1 | SNV | Missense_Mutation | | c.1084N>A | p.Glu362Lys | p.E362K | O43312 | protein_coding | tolerated(0.46) | benign(0.182) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MTSS1 | SNV | Missense_Mutation | rs762528178 | c.1930N>T | p.Arg644Trp | p.R644W | O43312 | protein_coding | tolerated(0.18) | possibly_damaging(0.84) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MTSS1 | SNV | Missense_Mutation | | c.252G>A | p.Met84Ile | p.M84I | O43312 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MTSS1 | SNV | Missense_Mutation | novel | c.1532N>T | p.Thr511Ile | p.T511I | O43312 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MTSS1 | SNV | Missense_Mutation | novel | c.1268N>C | p.Asp423Ala | p.D423A | O43312 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A204-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTSS1 | SNV | Missense_Mutation | rs149780096 | c.1395N>A | p.Met465Ile | p.M465I | O43312 | protein_coding | tolerated(0.46) | benign(0.023) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTSS1 | SNV | Missense_Mutation | novel | c.421N>G | p.Ser141Ala | p.S141A | O43312 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
MTSS1 | insertion | Nonsense_Mutation | novel | c.1292_1293insAAAAAATAATAATAAATAAA | p.Arg432LysfsTer6 | p.R432Kfs*6 | O43312 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |